The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial

Pegozafermin, a long-acting glycopegylated analog of human fibroblast growth factor 21, is in development for the treatment of severe hypertriglyceridemia (SHTG) and nonalcoholic steatohepatitis. Here we report the results of a phase 2, double-blind, randomized, five-arm trial testing pegozafermin a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatt, Deepak L., Bays, Harold E., Miller, Michael, Cain, James E., Wasilewska, Katarzyna, Andrawis, Nabil S., Parli, Teresa, Feng, Shibao, Sterling, Lulu, Tseng, Leo, Hartsfield, Cynthia L., Agollah, Germaine D., Mansbach, Hank, Kastelein, John J. P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353930/
https://www.ncbi.nlm.nih.gov/pubmed/37355760
http://dx.doi.org/10.1038/s41591-023-02427-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353930/
https://www.ncbi.nlm.nih.gov/pubmed/37355760
http://dx.doi.org/10.1038/s41591-023-02427-z

Ejemplares similares